Risk of Adverse Health Outcomes & Decrements in Performance due to Inflight Medical Conditions: ExMC Pharmacy Research Plan by Antonsen, Erik
VRD Final Baseline 092316          Page 1 of 21 
 
Risk:  Risk of Adverse Health Outcomes & Decrements in Performance due to 
Inflight Medical Conditions 
 
Gap: Med02: We do not have the capability to provide a safe and effective 
pharmacy for exploration missions. 
 
Responsible Element: Exploration Medical Capability (ExMC) 
 
Status: Open 
 
Rationale for Gap Med02 Research Plan   
 
The Exploration Medical Capabilities (ExMC) Element of NASA’s Human Research 
Program is charged with identifying medical capabilities that can address the challenges 
of prevention, diagnosis, and treatment of disease and injuries that could occur during 
exploration missions beyond Earth’s orbit.  Faced with the obstacle of access to in-flight 
medical care, and limitations of vehicle space, time, and communications; it is necessary 
to prioritize what medical consumables are manifested for the flight, and which medical 
conditions are addressed. Studies of astronaut health establish the incidence of common 
and high risk medical conditions that require medical intervention during long-duration 
exploration missions. In 2000, the Institute of Medicine (IOM) convened a committee of 
experts, Committee on Creating a Vision for Space Medicine during Travel beyond Earth 
Orbit, to examine the issues surrounding astronaut health and safety for long duration 
space missions. Two themes run throughout the committee’s final report: (1) that not 
enough is known about the risks to human health during long-duration missions beyond 
Earth’s orbit or about what can effectively mitigate those risks to enable humans to travel 
and work safely in the environment of deep space and (2) that everything reasonable 
should be done to gain the necessary information before humans are sent on missions of 
space exploration (IOM, 2001). Although several spaceflight focused pharmaceutical 
research studies have been conducted, few have provided sufficient data regarding 
medication usage or potency changes during spaceflight. The Du pharmaceutical 
stability study assessed medications flown on space shuttles to and from the 
International Space Station (ISS) from 2006 until 2008; of which some medications were 
still viable beyond their expiration dates (Du et al, 2011). However, as with many 
spaceflight studies, the small ‘n’ associated with this study limits the ability to draw strong 
conclusions from it. Dr. Wotring and others have recently published articles containing 
information regarding medication usage, indications, and efficacy gleaned from 
spaceflight records (Wotring et al, 2015, 2016; Barger et al, 2014; Basner and Dinges, 
2014).  Although some conclusions can be drawn from these studies, the inability to fully 
quantify medication usage, indications, side effects, and effectiveness, limits insight as to 
which medications should be prioritized for further research. 
https://ntrs.nasa.gov/search.jsp?R=20170001651 2019-08-31T17:24:59+00:00Z
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MED02 Research Plan Assumptions 
 
The results and outcomes based on the recommendations of this Element research 
plan are limited by regulatory and procurement restraints, and predictive solutions for 
unknown challenges that may be experienced during a Mars mission expected to occur 
in the 2030s.  Despite these limitations, the Element will proceed with the execution of 
this research plan with the goal of gathering as much data as possible, and learning as 
much as possible, to provide a safe and effective pharmaceutical formulary for use 
during exploration missions. 
 
Overview of the Strategy for Gap Mitigation 
 
The Med02 “Pharmacy” Gap identifies a strategy to ensure that medications used to treat 
medical conditions during exploration missions are available, safe, and effective.  It is clear 
that pharmaceutical intervention is an essential component of risk management planning 
for astronaut health care during exploration missions. Filling this Gap requires assembling 
a formulary that is comprehensive enough to prevent or treat anticipated medical events, 
and is chemically stable, safe, and robust enough to have sufficient potency to last for the 
duration of an exploration space mission. In cases where that is not possible, filling this 
Gap requires exploration of novel drug development techniques, dosage forms, and 
dosage delivery platforms that enhance chemical stability as well as therapeutic 
effectiveness. 
 
This research plan will outline the steps, processes, procedures, and research portfolio 
aimed at identifying a capability that will provide a safe and effective pharmacy for any 
specific exploration Design Reference Mission (DRM) by addressing seven critical 
questions: 
 
Question 1:  What medications do we think we need for a specific DRM? 
Question 2:  Of the full set of medications selected for a DRM, which will be effective 
throughout the journey and which will not? 
Question 3:  Of the medications that do not remain stable for the full mission 
duration, can we characterize their likely effective shelf life on a specific DRM? 
Question 4:  Can we provide the crew a way to determine in real time whether a 
medication is chemically stable, still active, or degraded? 
Question 5:  As the formulary medications degrade, will they become toxic? Will 
they remain safe and effective? 
Question 6:  Do alternative methods exist for supplying formulary medications for a 
DRM? Do alternative medications or treatments exist that could be supplied to a 
DRM? 
Question 7:  Can we modify existing properties of pharmaceuticals to minimize their 
resource footprint or improve their tolerance to the spaceflight environment? 
The proposed pathway for this research is outlined below in Figure 1.   
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Figure 1: Overview of the proposed pharmacy research pathway. 
 
The research portfolio consists of projects having the potential to lead to significant 
advances in astronaut health care. However, the research activities aimed at 
addressing the adverse medical outcomes anticipated during exploration missions 
focus on needs that differ from those associated with the International Space Station 
(ISS) and Space Shuttle missions that have formed the basis of our operational 
experience to date. To address the ExMC Element’s Med02 “Pharmacy” Gap, the 
research focus should be comprehensive across all areas of concern; crosscutting in 
that it should make use of a body of knowledge and evidence-based models and 
theories that are continually extended, refined, and revised; translational in that it 
should focus on expediting the discovery of new tools and treatments by using a 
multidisciplinary, highly collaborative "bench-to-bedside" approach (Woolf, 2008); and 
lastly, interventional, by using clinical studies where appropriate to verify the efficacy 
and safety of targeted treatments or preventive measures. 
 
The proposed approach to building this research portfolio is to seek research 
projects that concentrate on four major focus areas: 
 
1. Formulary selection (Critical Question 1) 
2. Formulary potency and shelf life (Critical Questions 2, 3, and 4) 
3. Formulary safety and toxicity (Critical Question 5) 
4. Novel technology and innovation such as portable real-time chemical analysis 
innovative drug therapies and dosage and delivery platforms (Critical Questions 
6 and 7). 
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Target deliverable for closure of gap 
 
A recommendation for a chemically stable, safe, and effective medication formulary that 
supports the operational needs of exploration space missions by FY2025. 
 
Procurement Mechanism(s):  Directed adjunct and supportive research as needed; 
solicited research projects 
 
Research Plan Development 
 
The Pharmacotherapeutics Discipline has partnered with the ExMC Element to develop 
and propose this research plan; which outlines the steps, processes, procedures, and 
research portfolio that will lead to closing the Med02 Gap by 2025 (pink and red flags in 
Figure 2). This plan will be reviewed and evaluated by a panel of experts from the 
pharmaceutical industry, regulatory, and academic scientific communities. Comments 
and recommendations from the expert panel report will be incorporated into the final 
research plan where applicable.  The structured research pathway, as illustrated in 
Figure 2, is needed to address the aforementioned critical questions, and thereby obtain 
as much knowledge as possible that will lead towards a safe and effective medication 
formulary for exploration missions.  
 
 
Figure 2: Visual description of the ExMC Med02 “Pharmacy” Gap mitigation strategy timeline, which 
provides a broad overview of the targeted schedule for project initiation (blue flags) and an illustration of 
project chronology and overlap, while highlighting expected deliverables, shown as interim milestones (pink 
flags), and major milestones (red flags). 
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Deliverables for research plan development 
 
1. The Pharmacotherapeutics Discipline and the ExMC Element develop a draft research 
plan that defines the steps, processes, procedures, and research portfolio targeted at 
closing the Med02 Gap by 2020 (end of 2nd Q, FY16). 
2. The draft research plan is reviewed by ExMC and Medical Operations stakeholders; 
the subsequent baseline research plan is presented at the ExMC weekly Forum 
(beginning of 4th Q, FY16). 
3. The baseline research plan is updated in response to feedback from the ExMC Forum 
(by end of 4th Q, FY16). 
4. Solicitations are initiated for recommendations of candidates to participate on the 
panel of pharmaceutical science experts from the pharmaceutical industry, regulatory 
agencies, and academia (by end of 4th Q, FY16). 
5. The list of prospective expert panelists is vetted by Pharmacotherapeutics and ExMC 
stakeholders and narrowed down to a list of finalists, who will be sent invitations (1st 
Q, FY17). 
6. The meeting of invited expert panelists convenes to review the baseline research plan 
(2nd Q, FY17). 
7. An expert panel proceedings report is developed; it includes panelist 
recommendations that will be incorporated into the final research plan (by end of 2nd 
Q, FY17). 
 
Formulary Selection 
 
Critical Question 1: What medications do we think we need for a specific Design 
Reference Mission (DRM)? 
 
Exploration space missions pose several challenges to providing a comprehensive 
medication formulary designed to accommodate the size and space limitations of the 
spacecraft; while addressing the individual medication needs and preferences of the 
crew, the negative outcome of a degrading inventory over time, the inability to resupply 
before expiration dates, and the need to properly forecast the best possible medication 
candidates to treat conditions that will occur in the future. The NASA Lifetime Surveillance 
of Astronaut Health (LSAH) proactively collects data on astronaut medical care and 
workplace exposures, especially those occurring in the training and spaceflight 
environments, and conducts operational and health care analyses to look for trends in 
exposure and health outcomes. NASA’s Life Sciences Data Archive also includes data 
from human subjects derived from both past and current spaceflights, as well as data 
from analog studies. The majority of the medical occurrences that have affected NASA 
astronauts during previous space missions, and that were captured by the incidence data 
from the Integrated Medical Model (IMM) update, could be treated or mitigated by 
medications. Pharmacy needs and medication class recommendations to address the 
identified medical occurrences will be received from the Concept of Operations (MED01) 
Team and implemented in the research plan as warranted. 
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The conceptual design of the exploration mission formulary and the components 
assembled to construct it is as important as the medication contents themselves. An 
ideal exploration mission formulary design would have three components (Figure 3). The 
first component, and largest inventory in the exploration mission formulary, would be the 
centralized Core Formulary. The Core Formulary would consist of an inventory of 
medications accessible to all crewmembers, including representative medications from 
therapeutic classifications targeted at treating common and priority medical events and 
conditions identified by previous studies, data mining, and scientific literature, and as 
captured in NASA’s and other space agencies’ archival data, and those predicted using 
simulation and modeling technology. Studies have shown that drug compounds are often 
therapeutically classified according to their chemical structures. It is hypothesized that 
drugs currently used and future, possibly superior drug compounds from the same 
therapeutic classifications; will have similar chemical structures and degradation 
behaviors. Studies have also demonstrated the ability to predict drug indications and 
drug side effects on the basis of the chemical structure of the drug (Keiser et al., 2009; 
Scheiber et al., 2009; Atias and Sharan, 2011; Pauwels et al., 2011). Therefore, as 
opposed to selecting specific medications available today that may become obsolete or 
replaced by superior medications in the future; a list of therapeutic classifications will be 
compiled targeting prevention and/or treatment of medical problems anticipated during 
exploration missions. (Information on medical problems anticipated during exploration 
missions will be obtained from the Concept of Operations (MED01), ExMC Risk Analysis 
(MED08), and the Exploration Medical Condition List.) One or two candidate medications 
from each therapeutic classification that show evidence of exceptional chemical stability 
and efficacy performance as demonstrated operationally, or in the literature; will be 
selected for further evaluation for prospective use in an exploration mission Core 
Formulary. The Core Formulary will be managed in a format similar that of a “Pyxis” 
delivery system in a hospital, which enables medication use tracking for mission risk 
assessment. This information will be processed through the Medical Data Architecture 
(MED07) and the In-Flight Risk Posture (MED09) tools.  
 
The second component of the exploration mission formulary would be a small inventory 
of personalized medications for each crewmember. The Crewmember Personalized 
Medicine Component would consist of crewmember-specific maintenance drugs and a 
few less critical medications (including herbal and nutritional supplements) based on 
individual crewmember preferences. Selection of crewmember-specific medications will 
be based on astronaut preference and on the personalized medicine needs of 
crewmembers. Information from the Pharmacy research pathway will be made available 
to the Personalized Medicine Gap (MED03) to assist with selection of high-yield 
medications and to ensure that the operational needs of the exploration DRM are met. 
 
The final component of the exploration mission formulary would be another centralized 
but smaller inventory of medications dedicated to emergency medicine and designed to 
address medical conditions or injuries requiring immediate or urgent medical attention.  
 
 
 
VRD Final Baseline 092316   Page 7 of 21 
 
These medications are considered critical to initial patient stabilization, and require ready 
accessibility within the medical area of the transit or planetary habitat. Medication 
selection for this component is also contingent on recommendations from the Concept of 
Operations (MED01) and the Ethics Research Pathway (MED06). 
                       
Figure 3: The proposed formulary will have three components:  
 The largest, “Core Formulary,” will be a centralized, shared inventory consisting of medications 
identified as high use or of significant or priority need.  
 The second will be a smaller, personalized medication inventory containing no more than five 
chronic condition maintenance or preferred therapies, as selected by each crewmember.  
 The final component will be a small inventory of crucial emergency medications. 
 
Deliverables for answering Critical Question 1 
 
1. Element Directed (ExMC Element Scientist, Clinical and Research Pharmacists): A list 
consisting of candidate medications from targeted therapeutic classifications aimed at 
addressing medical events anticipated to be experienced during exploration space 
missions (1st Q, FY17); as suggested by 
a. Apollo, ISS, and Shuttle medical logs, and Mercury and Gemini mission data 
b. The NASA Lifetime Surveillance of Astronaut Health (LSAH) 
c. NASA’s Life Sciences Data Archive 
d. Integrated Medical Model (Fig. 4.0) 
e. Medical Optimization Network for Space Telemedicine Resources (MONSTR) 
f. International Space exploration program data 
g. Occupational Health Tracking data as available 
h. Dose Tracker experimental data recorded from flight 
i. Medical Consumables Tracker experimental data recorded from flight 
2. Element Directed (Research Pharmacist): Ongoing surveillance of clinical / scientific 
research, literature, and the approved pharmaceutical industry pipeline to assist with 
identification of promising Core Formulary medication candidates from the targeted 
therapeutic classifications aimed at addressing the anticipated medical events 
(beginning 1st Q, FY17).  Drug information sources used: 
a. Pharmaceutical manufacturers 
b. Literature 
c. Research organization data sharing 
3. Element Directed (Research Pharmacist, Potomac Institute): An *annual report 
highlighting promising Core Formulary medication candidates identified from ongoing 
surveillance activities to the ExMC Element Scientist (1st Q, FY18). 
Emergency 
Medicine 
Personalized Formulary 
5 selected medication  
preferences / crewmember
 
Core Formulary 
Top 20 (high use / need) Medications 
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Formulary Potency and Shelf Life 
 
Critical Question 2: Of the full set of medications selected for a DRM, which will be 
effective throughout the journey and which will not? 
 
a. What are the effects of the deep space environment on medication shelf life with 
respect to therapeutic effect? 
b. Are there alternatives to current formulary selections that would have a sufficient shelf 
life to last for the duration of an exploration spaceflight mission? 
 
The unique physical and environmental factors (e.g. radiation) of space missions may 
contribute to the instability of pharmaceuticals. It is of clinical importance to determine 
whether medications included in an exploration mission formulary would be vulnerable to 
more rapid degradation precipitated by the radiation environment of deep space. 
Degradation of pharmaceutical formulations can result in inadequate efficacy and/or 
untoward toxic effects that may compromise astronaut safety and health. NASA has 
conducted research to determine whether medications flown in space would remain 
viable after being exposed to the environmental conditions of spaceflight. Results from 
those studies suggest that some medications are inherently unstable when exposed to 
spaceflight conditions. Also, a number of medications showed significant degradation of 
active drug content after flight relative to matching ground controls. Temperature and 
relative humidity rarely exceeded the maximum recommendations for storage in the 
Shuttle and ISS, suggesting that radiation exposure and the long-term storage anticipated 
during exploration missions are more likely to be responsible for any pharmaceutical 
degradation (Du et al., 2011). Although pharmaceutical degradation possibly due to 
radiation exposure at low Earth orbit has been addressed by past research projects 
reported in the literature (Du et al., 2011; Putcha et al., 2011); these environments don’t 
adequately capture the chemical and physical changes that may occur with exposures to 
the radiation environment outside the Earth’s magnetic sphere. Therefore, it is unknown 
how radiation in deep space will affect the degradation rates of medications in an 
exploration mission formulary. 
 
Gamma irradiation has been used as a method of microbial sterilization in the food, 
medical device, and to a lesser extent, pharmaceutical industries. However, the use of 
gamma irradiation on pharmaceutical products can result in a loss of active 
pharmaceutical ingredient (API) potency, the creation of radiolysis byproducts, and a 
reduction of the molecular weight of polymer excipients, and can influence drug release 
from the final product. Despite these risks, use of gamma sterilization has continued to 
increase and demonstrate strong applicability to a wide range of pharmaceutical products. 
The increased interest in this technique is likely the result of the discovery of new insights 
into compatibility of some pharmaceutical products with radiation, and optimization of the 
radiation dose and environmental conditions to limit product degradation during 
sterilization. A recent literature review article (Hasanain et al., 2014), summarizing utility 
and feasibility of gamma sterilization in the pharmaceutical industry, discussed how 
potentially harmful high ionization energy from gamma irradiation can be harnessed and 
optimized by formulation changes (i.e. addition of radioprotectants), or by varying the 
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irradiation conditions (temperature, product state, oxygen environment, dose, and dose 
rate). The advancements made in gamma sterilization research may have further 
application for pharmaceutical products used during an exploration spaceflight mission. 
However, the potential damage and subsequent solutions for these products when they 
are exposed to the forms of ionizing radiation found in deep space (i.e. galactic cosmic 
rays, solar energetic particles), may be considerably different from damage resulting from 
gamma sterilization and solutions to prevent or counteract such damage. Ideally, stability 
studies would be capable of characterizing quality, chemical integrity, and safety of 
medications exposed to the deep-space environment. However, in the absence of 
obtaining those characterizations from deep-space exposure, a close environmental 
analog such as the ISS or targeted radiation exposure could reveal additional insight that 
could bring us closer to that safe and effective exploration mission medication formulary. 
 
Medications that are unlikely to remain safe and effective throughout the exploration 
mission duration will be considered for stability testing. Stability testing is terrestrially 
required to demonstrate that a pharmaceutical product meets its acceptance criteria 
throughout its shelf life and to gain regulatory approval for commercialization. The 
purpose of stability testing is to provide evidence of how the quality of a drug substance 
or formulated drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, and light, and to establish a shelf 
life for the drug product and recommended storage conditions (ICH Q1A R2, 2003). 
Stability testing is costly in terms of resources and time; therefore the above prioritization 
steps will be taken before any medications are considered. However, the opportunity to 
perform well designed stability studies in the past has been limited by the lack of 
matching controls for comparing stability test results with flight medications.. This will be 
addressed by ensuring that matching control medications are available for those 
prioritized medications retrieved from spaceflight; thereby enabling control-based drug 
stability analysis. 
 
A stability study is a designed experiment in which the pharmaceutical product is stored in 
environmental chambers and followed for a prescribed amount of storage time. 
Periodically the product is sampled to measure a series of stability-limiting properties. 
During a stability study, testing processes are developed to evaluate pharmaceutical 
quality attributes, such as API identity, concentration, and purity. Additionally, the 
capability of a particular finished dosage form in a specific container/closure system to 
remain within its physical, chemical, microbiological, toxicological, protective, and 
informational specifications are defined (Kommanaboyina et al., 1999). Any changes to 
those drug properties beyond the accepted criteria could risk patient safety, as by 
delivering a less than efficacious dose or toxic degradation products (Huynh-Ba, 2009). 
The Food and Drug Administration (FDA) requires that pharmaceutical companies 
determine a time limit within which they can guarantee the full potency and safety of 
medications. This time limit, or shelf life, is typically 1-2 years from the medication 
manufacture date if the product remains stored in the original unopened container, under 
optimal environmental conditions. A drug product’s shelf life or expiration dating period is 
defined as the time period during which that drug product is expected to remain potent 
within approved specifications, provided that it is stored under the conditions defined by 
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the manufacturer on the container label [FDA Guidance for Industry Q1A(R2)]. 
Degradation reactions like oxidation, reduction, hydrolysis, or racemization can play a 
vital role in stability of a pharmaceutical product, and depend on conditions such as 
concentration of reactants, pH, radiation, and presence of catalysts. A finished 
pharmaceutical product may also undergo changes in appearance, consistency, content 
uniformity, clarity, moisture contents, particle size and/or shape, pH, or package integrity, 
which may be a result of impact, vibration, abrasion, or environmental factor fluctuations 
and may cause the product to require further testing processes and evaluations (such as 
tests for tablet hardness, friability, dissolution, and diffusion). Therefore, it is possible that 
the conditions of deep spaceflight may still affect the labeled shelf life of medications even 
when they are sealed in their original manufactured packaging. Planetary exploration 
missions include DRMs that have timelines in excess of 2.5 years for total mission 
duration. Given a lack of ability to resupply these missions, it may be necessary to 
perform stability studies with selected high-priority medications that appear unlikely to last 
the full mission duration. 
 
Shelf life determined by stability testing can be expensive and time-consuming. Ideal 
ground-based analogs mimicking the environmental conditions of exploration missions 
are unavailable; therefore, predictive stability modeling methodologies that offer 
statistically accurate estimations should also be considered. Statistical models are 
mathematical descriptions of how the data are produced and how they vary from 
observation to observation (Littell et al., 2006). The Product Quality Research Institute 
(PQRI) Stability Shelf Life Working Group (SSLWG), a collaborative involving experts 
from FDA’s Center for Drug Evaluation and Research, the pharmaceutical industry, and 
academia, was established in late 2006 to investigate current and alternative statistical 
methods for estimating the shelf life of pharmaceuticals from stability data. The PQRI 
SSLWG developed a modeling context that could be extended to linear or nonlinear 
regression over time, and is guided by three premises: (1) the two primary processes 
giving rise to observations are variation among batches, and changes in a batch over 
time; (2) the observed response is a function of these two processes; and (3) following 
ICH guidance, changes over time follow a linear regression (Stroup and Quinlan, 2010). 
So far, Stroup and Quinlan have characterized five methodologies to estimate 
pharmaceutical shelf life. Statistical modeling techniques may prove to be useful tools for 
predicting shelf life of pharmaceutical formulary candidates for exploration spaceflight. 
 
Deliverables for answering Critical Question 2 
 
Data Mining 
 
1. Element Directed: A catalogue of labeled shelf lives for selected medications in their 
original manufactured packaging  
2. A list, based on information provided by the manufacturer and scientific literature, 
consisting of proposed medications that are verified to maintain labeled shelf life in 
original packaging 
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Ground-based Stability Studies 
 
1. Element-directed or solicited ground-based pharmaceutical stability studies as needed 
to characterize the robustness of medications from the list of selected therapeutic 
classification drug candidates (end of 2nd Q, FY17). 
a. Medications will be selected on the basis of prioritization and retrieved from ISS 
down-mass, to provide opportunities for ground analysis. 
b. Sufficient medications will be procured as needed to provide matching (identical 
manufacturer and lot) control samples to support ground-based pharmaceutical 
stability stress testing and analytical identification with portable assessment 
technology. 
2. Stability reports characterizing shelf life of tested drugs, and results of all physical and 
chemical stability tests (within 1-2 years of award, contingent on award criteria).  
a. These reports will be produced by stability studies to maximize effort, time, and 
resources, there will be no duplication of study drugs between directed and 
solicited investigational sites. 
 
Shelf Life Estimation / Predictive Modeling Studies 
 
1. Element-directed and solicited studies employing predictive stability modeling 
programs (i.e. linear, nonlinear, or quantile regression modeling programs), to 
statistically estimate shelf life of selected medications from the list of the selected 
therapeutic classification drug candidates to aid in the identification of the most robust 
medications (end 2nd Q FY17) 
2. Predictive reports, produced by these studies, with shelf life estimation results for all 
medications tested (within 1-2 years of award, contingent on award criteria) 
 
 
Critical Question 3:  Of the medications that do not remain stable for the full 
mission duration, can we characterize their likely effective shelf life on a specific 
DRM? 
 
a. Are there medications that don’t have a shelf life problem if they stay in the original 
packaging? 
b. If so, how much extra volume and mass does keeping the original packaging add? 
 
For different DRMs the answer to Critical Question 2 above will depend on the expiration 
dates of the medications in the original packaging. Proposed medications for the 
exploration formulary will be assessed, and known information about medication 
expiration durations will be catalogued and compiled into a list. Should selected 
medications identified as being able to last for the duration of an exploration spaceflight 
journey require an operational need for repackaging, reevaluation would be needed to 
establish a shelf life beyond the required one year from the repackaging date. This list of 
medications that require reevaluation can be even further reduced and prioritized to limit 
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expenditure of research resources. This approach of reduction and prioritization will rely 
on available evidence extracted from the literature and shelf life data provided by 
manufacturers for the proposed formulary therapeutic classifications or specific 
medications under consideration. 
 
Deliverables for answering Critical Question 3 
 
1. Element Directed: A feasibility assessment of proposed exploration spaceflight 
formulary medications, conducted by the operational pharmacy at Johnson Space 
Center to determine which medications can be made available in their manufactured 
packaging for exploration spaceflight missions. 
2. A report distinguishing those medications that can be flown in original manufactured 
packaging from those that cannot, provided by the operational pharmacy. 
 
Critical Question 4: Can we provide the crew a way to determine in real time 
whether a medication is chemically stable, still active, or degraded? 
 
Standard methods for pharmaceutical analysis to determine API content involve the use 
of high- and/or ultra-performance liquid chromatography (HPLC/UPLC). This technique 
requires destruction of the samples by extraction of the API into organic solvent mixtures 
and water. Currently, nondestructive optical spectroscopy methods such as infrared and 
Raman spectroscopy are being used for chemical structural identification of drugs by the 
pharmaceutical industry. For over a decade handheld Raman technology was used to 
monitor purity of pharmaceutical raw materials, providing rapid information about the 
chemical structure and related physical or biopharmaceutical properties of all types of 
pharmaceutical dosage forms. Handheld Raman devices with both qualitative and 
quantitative capabilities are being developed for more comprehensive spectroscopic 
analyses of pharmaceuticals. Researchers from the U.S. Food and Drug Administration 
have demonstrated that the transfer of a spectral library and chemometric-based Raman 
methods across different Raman handheld devices is feasible (Hajjou and Lukulay, 2014). 
Infrared spectroscopy is a versatile method for fingerprinting and identification of 
pharmaceutical compounds and functional groups within molecules. It measures energy 
absorption across the infrared frequency range. Gas, liquid, or solid pharmaceutical 
samples can be analyzed by infrared spectroscopy. The Fourier transform infrared (FTIR) 
spectroscopic method allows simultaneous analysis across the infrared frequency range. 
Due in part to its speed and sensitivity, FTIR has become the standard of pharmaceutical 
infrared spectroscopic analysis. Technological advances over the past two decades in 
areas such as lasers, batteries, software, and micro electromechanical systems (MEMS) 
now allow  manufacturers to routinely design and build rugged, compact, portable FTIR 
instruments whose performance is the same or even better than that of benchtop 
systems. This rapidly evolving technology provides nondestructive analytical capabilities 
that would optimize care during exploration missions. 
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Deliverables for answering Critical Question 4 
 
1. Element-directed or solicited proof-of-concept studies designed to validate utility for 
exploration missions of novel commercial off-the-shelf (COTS) portable technology 
designed to perform nondestructive, real-time assessment and characterization of 
chemical integrity and active pharmaceutical ingredient content available in 
medications (end 2nd Q FY17) 
a. Raman spectroscopy (Hajjou and Lukulay, 2014) 
b. Fourier transform infrared (FTIR) spectroscopy (Matkovic et al., 2005) 
c. Miniature mass spectrometer (Keil et al., 2007) 
d. Portable GC/MS (Biemann et al., 1976; Gloeckler et al., 1995) 
2. The medications analyzed are identical (matching manufacturer and lot) to those 
tested by the ground-based pharmaceutical stability stress tests. 
3. A report from each study summarizing proof of concept for each device evaluated, 
assessment and characterization of chemical integrity and API content available in the 
medications tested, and a feasibility assessment for exploration utility (within 1-2 years 
of award, contingent on research award timeline). 
4. Comparison of results with those obtained by standard liquid chromatographic (HPLC 
/ UPLC) analyses for validation (end of 2nd Q FY18 or FY19, contingent on research 
award timeline). 
5. Exploration of customized development leading to a more robust device able to 
withstand the harsh spaceflight environment (e.g microgravity), assess multiple drug 
classes, and modular in that we can add to the spectral library. 
 
Formulary Safety and Toxicity 
 
Critical Question 5: As the formulary medications degrade, 
a. will they become toxic? 
b. will they remain safe and effective? 
 
Once the prospective formulary for exploration is selected, it may be desirable to 
establish the chemical and physical stability of selected medication compounds, as well 
as their safety, by identifying degradation profiles and products. The formation of toxic 
degradation products is a potentially critical quality and patient safety issue for exploration 
mission formulary medications. It is important to determine whether degradation products 
are therapeutically active, characterize the activity, and evaluate the toxicity profile for 
degradation products of each formulary medication. A well- designed in vivo toxicology 
study would include exposing a suitable animal model to degraded medications or 
isolated degradation products of a selected medication to ascertain drug safety profiles. 
Although the pharmacokinetics of toxic drug degradation products may have an impact on 
product safety, these data are frequently unavailable. Traditionally, evaluation of the 
safety of new chemicals and pharmaceuticals requires regulatory studies in animals, 
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designed to protect human health and the environment. Generally, risk assessment can 
be viewed as a process by which information from various sources (e.g. in vitro, in silico, 
and in vivo studies) is combined to characterize a particular chemical or molecular entity. 
Ideally, chemical and drug development would be front-loaded with experiments that can 
definitively select safe compounds as quickly as possible. Three-dimensional (3D) cell 
and tissue models bring us ever closer physiologically to the in vivo situation. The 
incentive to use novel in vitro methods is high because being able to manipulate the test 
system is advantageous, as it may provide a more thorough understanding of potential 
mechanisms of toxicity and the human and animal response to exposure to foreign 
chemicals. Another novel approach for product risk assessment incorporates the 
prediction capability of physiologically based pharmacokinetic (PBPK) models into a 
rational drug degradation risk-assessment procedure using a series of model drug 
degradants (substituted anilines). The PBPK models are parameterized using a 
combination of experimental and literature data, and computational methods. Relative to 
traditional risk-assessment calculations, this novel PBPK approach seems to provide a 
rational basis for drug instability risk assessment by focusing on target tissue exposure 
and leveraging physiological, biochemical, and biophysical knowledge of compounds and 
anatomy and physiology of the targeted animal model species. As data accumulate to 
support the predictive validity of in silico and in vitro studies for human safety, these 
techniques will enable compounds to be deselected earlier in development, thereby 
limiting the need for animal testing (Chapman et al., 2013). 
 
Deliverables for answering Critical Question 5 
 
Toxicity Studies 
 
1. Studies (in vivo and/or in vitro) directed or solicited on an as-needed basis to identify 
degradation profiles of selected medications from the targeted therapeutic 
classifications proposed for the exploration space medical kit formulary. Determination 
of whether degradation products are therapeutically active, characterization of the 
activity, and evaluation of the toxicity profile for degradation products (3rd Q FY17). 
2. Reports, delivered by studies, that summarize results of toxicity studies including 
identified and characterized degradation and toxicity profiles of the selected 
medications from the targeted therapeutic classifications (The bolded text indicates 
major milestones, as defined in previous versions, since deleted.  Can remove, to be 
consistent with new format).  (1-2 years post initiation – 3rd Q FY18, Y19, in 
accordance with award timeline). 
3. As needed, identification of an ideal animal model and solicitation or direction of in 
vivo toxicology animal (flight and/or ground) studies using degraded medications or 
isolated degradation products from the selected medications to ascertain drug safety 
profiles (initiate 1st Q FY20). 
4. Reports, delivered by studies, that summarize results of in vivo animal model toxicity 
studies and include defined safety profiles of the tested selected medications from the 
targeted therapeutic classifications (1-2 years post initiation – 1st Q FY21, or FY22, in 
accordance with award timeline). 
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5. A final list of tested medications now verified as safe will be recommended to be 
considered as the target Core medication formulary for exploration missions (by 
FY2022). 
 
Dosing Monographs 
 
1. For select degraded medications with reduced API, but verified as safe, incorporation 
of degradation and safety profiles from previous work to identify modeling technology 
with the capability to generate dosing monographs adjusted for decreasing API 
content (initiate 1st Q, FY22). 
2. Studies directed and/or solicited as needed to generate dosing monographs adjusted 
for decreasing API content, using identified modeling technology, and degradation and 
safety profile results from previous studies (2nd Q, FY22). 
3. Reports, delivered by studies, that include recommended dosing monographs for 
medications with reduced API but verified as safe (VAS), selected from the targeted 
therapeutic classifications list (by end of 2nd Q, FY2024). 
 
Novel Technology and Innovation 
 
Critical Question 6: Do alternative methods exist for supplying formulary 
medications for a DRM?  
 
Critical Question 7: Can we modify existing properties of pharmaceuticals to 
minimize their resource footprint or improve their tolerance to the spaceflight 
environment? 
 
As society’s demands for safe and efficacious medications grow, technological solutions 
have become essential to reducing barriers to clinical success. Technology can contribute 
to a research plan for exploration missions by helping to provide better target selection 
and validation of disease pathophysiology, identifying more predictive and biologically 
relevant high-throughput assays, and acquiring pharmacology and toxicology data early, 
thereby eliminating time and resources expended on formulary candidates with poor 
safety profiles. Pharmaceutical interventions, including sustained and targeted delivery 
technologies such as controlled-release topical, subcutaneous, intranasal, and inhalation 
dosage forms, may provide for exploration missions the preventive health care solutions 
that are not currently addressed by standard pharmaceutical care (Putcha et al., 2011).  
 
In recent years, considerable research has been done on preparing materials and finding 
new uses for nanoscale structures in drug delivery. Uses such as carriers for controlled 
and targeted drug delivery, micro patterned devices, and systems for biological 
recognition have demonstrated the versatility of these materials (Langer, 2003). 
Nanostructures also have the abilities to protect drugs encapsulated within them from 
physiologic degradation and to target their delivery with sustained release, and they are 
suitable for oral administration (Ochekpel et al., 2009). Nanotechnology has proven 
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capable of revolutionizing most areas of technology critical to NASA’s future missions 
(Baker Institute Policy Report, 2012). Promising ideas for novel therapeutic intervention 
for pharmaceuticals, medical imaging and diagnostic capabilities, and implant and tissue 
regeneration materials offer opportunities to improve astronaut health management and 
provide solutions for many of clinical medicine's unsolved problems. University College 
London scientists demonstrated the feasibility of fused-filament 3D printing (FF 3DP) to 
fabricate drug-loaded tablets and have shown that the release profiles obtained can be 
modified by careful selection of the printing parameters. The results immediately suggest 
that FF printing could offer a new method of manufacturing for personalized-dose 
medications and/or for tablets prepared at the point of use (Goyanes et al., 2014). 
 
Deliverables for answering Critical Questions 6 and 7 
 
Pharmaceutical Performance Enhancement 
 
1. Technology Watch Element Directed (initiated 1st Q FY17, ongoing).  Exploration of 
novel drug development techniques, dosage forms, and delivery systems for the 
selected formulary medications, with the goal of improving stability, pharmacokinetic, 
and pharmacodynamic outcomes (Pharmacotherapeutics Discipline Research 
Pharmacist, Potomac Institute). 
a. Dosage form and delivery platforms (Including but not limited to the following): 
nanotechnology, gene therapy, and biomaterials (Edelhauser et al., 2010; Putcha 
et al., 2011; Langer and Peppas, 2003; Ochekpe et al., 2009; Baker Institute, 
2012; Seigneuric et al., 2010; Sajja et al., 2009; Felnerova et al., 2004; Pridgen et 
al., 2013; Hoare and Kohane, 2008; Peppas, 2005). 
b. Three-dimensional (3D) printing technology (Goyanes et al., 2014).  Different types 
of complex oral drug delivery devices have been fabricated using the 3DP process: 
immediate-extended release tablets, pulse release, breakaway tablets, and dual 
pulsatory tablets (i.e. diclofenac sodium). 
2. Annual report summarizing promising technology that could enhance the space 
exploration medication formulary, submitted by the Pharmacotherapeutics Discipline 
(Research Pharmacist) (annually, starting 1st Q, FY18). 
 
Technology Proof of Concept 
 
1. Element-directed or solicited proof-of-concept studies for COTS drug formulations, 
devices, drug development platforms, and delivery systems (1st Q FY18). 
2. Reports, delivered by studies, that summarize proof of concept for each COTS drug 
formulation, device, drug development platform, and delivery system evaluated, 
including feasibility assessment for exploration utility (1st Q, FY19 or 20, as defined by 
award timeline). 
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Pharmacokinetic / Pharmacodynamic Studies 
 
1. Element-directed or solicited comparative PK / PD studies using novel dosage forms 
or delivery platforms of medications selected from the prioritized lists developed from 
targeted therapeutic classifications to verify superior performance (1st Q, FY17) 
2. Studies will deliver a report summarizing results of comparative PK/PD studies (1st Q, 
FY19 or 20, as defined by award timeline).  
3. Recommendation of promising products for further testing as prospective candidates 
for the exploration mission formulary (2nd Q, FY20). 
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Figure 4.0: Visual description of the proposed ExMC Med02 “Pharmacy” Gap projects (blue boxes) illustrating 
non-sequential or grouped project relationships, and highlighting significant deliverables (green boxes). 
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